iCo completes DME drug Phase 2 clinical supply manufacturing
iCo is evaluating potential clinical activities in several regulatory jurisdictions, including Canada, where it has received a No Objection Letter from Health Canada’s Therapeutic Products Directorate related to
Advertise With UsAdvertise on our extensive network of industry websites and newsletters.
Get the PBR newsletterSign up to our free email to get all the latest PBR
news.